Aktuellt
SENASTE
We initiate coverage of OssDsign, a medtech company poised to benefit from the structural growth trends of an ageing population, stretched healthcare budgets and technological advancement. With a new franchise, Catalyst, giving the company exposure to a substantially larger market, the company looks ready for rapid growth, in our view. Our DCF analysis yields a fair value range of SEK 5-15 per share with a mid-point equity value of SEK 9.
LÄS MER
